Robert A Lazarus

US Patent:

6348343, Feb 19, 2002

Filed:

Feb 28, 2001

Appl. No.:

09/796774

Inventors:

Robert A. Lazarus - Millbrae CA
Steven Shak - Burlingame CA
Jana S. Ulmer - San Rafael CA

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C12N 922

US Classification:

435199, 424 946, 536 232

Abstract:

The present invention relates to amino acid sequence variants of human DNase I that have reduced binding affinity for actin. The invention provides nucleic acid sequences encoding such actin-resistant variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of actin-resistant variants of human DNase I.

US Patent:

6391607, May 21, 2002

Filed:

Jun 14, 1996

Appl. No.:

08/663831

Inventors:

Robert A. Lazarus - Millbrae CA
Clark Qun Pan - San Francisco CA

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C12N 900

US Classification:

435199, 435183, 435195, 435196, 424 946

Abstract:

The present invention relates to amino acid sequence variants of human DNase I that have increased DNA-hydrolytic activity. The invention provides nucleic acid sequences encoding such hyperactive variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of hyperactive variants of human DNase I.

US Patent:

7084109, Aug 1, 2006

Filed:

Jul 25, 2002

Appl. No.:

10/202915

Inventors:

Mark S. Dennis - San Carlos CA, US
Charles Eigenbrot - South San Francisco CA, US
Robert A. Lazarus - Millbrae CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 38/00
C07K 14/00

US Classification:

514 2, 514824, 435 71, 530300, 530326, 530325, 530324

Abstract:

This invention provides novel compounds which prevent or block a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention bind Factor VIIa (FVIIa), its zymogen Factor VII (FVII) and/or block the association of FVII or FVIIa with a peptide compound of the present invention. The invention also provides pharmaceutical compositions comprising the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.

US Patent:

7164002, Jan 16, 2007

Filed:

Jan 30, 2003

Appl. No.:

10/356257

Inventors:

Robert A. Lazarus - Millbrae CA, US
Henry R. Maun - San Francisco CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C07K 1/00
C07K 14/00
C07K 17/00

US Classification:

530350

Abstract:

This invention provides novel compounds which prevent or block a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention bind Factor VIIa (FVIIa ), its zymogen Factor VII (FVII). The invention also provides pharmaceutical compositions comprising the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.

US Patent:

7256027, Aug 14, 2007

Filed:

Jun 15, 1999

Appl. No.:

09/332886

Inventors:

Robert A. Lazarus - Millbrae CA, US
Mark Hurle - Bridgeport PA, US
Stephen Anderson - Princeton NJ, US
David B. Powers - Somerset NJ, US

Assignee:

Rutgers, the State University of New Jersey - New Brunswick NJ

International Classification:

C12N 9/02
C12N 15/00
C12N 1/20
C12Q 1/20
C12Q 1/00
C12Q 1/26
C12Q 21/04
C07H 21/04

US Classification:

435189, 435440, 435 4, 435 6, 435 25, 4352523, 4353201, 435 691, 435 711, 536 232, 536 237

Abstract:

Mutants of 2,5-diketo-D-gluconic acid reductase A, an enzyme used to produce 2-keto-L-gulonic acid, a precursor of ascorbic acid (vitamin C) are prepared by site-directed mutagenesis. These mutants have increased catalytic activity, increased expression levels, and/or enhanced temperature stability.

US Patent:

7407785, Aug 5, 2008

Filed:

May 3, 2004

Appl. No.:

10/838691

Inventors:

Robert A. Lazarus - Millbrae CA, US
Clark Qun Pan - San Francisco CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C12N 9/16
C12N 9/14
C12N 9/00
C07K 14/00
A61K 38/46
C12P 21/00
C12Q 1/44
C12Q 1/00
C12Q 1/68
C12N 15/00
C12N 5/10
C12N 1/21
C07H 21/00

US Classification:

435196, 435 19, 435 691, 4353201, 4352523, 435325, 435 4, 435 6, 435183, 435195, 536 232, 530350, 424 946

Abstract:

The present invention relates to amino acid sequence variants of human DNase I that have increased DNA-hydrolytic activity. The invention provides nucleic acid sequences encoding such hyperactive variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of hyperactive-variants of human DNase I.

US Patent:

7737115, Jun 15, 2010

Filed:

Apr 17, 2006

Appl. No.:

11/406067

Inventors:

Daniel K. Kirchhofer - Los Altos CA, US
Robert A. Lazarus - Millbrae CA, US
Christian Wiesmann - Brisbane CA, US

Assignee:

Genetech, Inc. - South San Francisco CA

International Classification:

A61K 38/18

US Classification:

514 12

Abstract:

The invention provides HGF/Met modulators comprising HGF having mutations in regions that affect HGF function, and antagonists that target said regions. The invention further provides methods of identifying, making and using these modulators.

US Patent:

8110377, Feb 7, 2012

Filed:

Apr 27, 2010

Appl. No.:

12/768557

Inventors:

Daniel K. Kirchhofer - Los Altos CA, US
Robert A. Lazarus - Millbrae CA, US
Christian Wiesmann - Bottmingen, CH

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 38/18
C07K 14/475
C07H 21/04
C12P 21/06

US Classification:

435 691, 530399, 530350, 514 95, 536 235

Abstract:

The invention provides HGF/Met modulators comprising HGF having mutations in regions that affect HGF function, and antagonists that target said regions. The invention further provides methods of identifying, making and using these modulators.